Drug intelligence / Profile preview

interferon beta + interferon gamma

Development stage
Preclinical
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intramuscular, Intravenous, Topical
01

Overview

Interferon beta + interferon gamma is a combination of two recombinant cytokines, both members of the interferon family. Interferons are proteins with antiviral, immunomodulatory, and antiproliferative properties. Interferon beta (a type I interferon) upregulates MHC class I expression and enhances cytotoxic T cell responses, while also inducing key antiviral mediators. Interferon gamma (the only type II interferon) is primarily produced by activated T lymphocytes and natural killer cells; it has antitumor properties, broad immunoregulatory effects, and can synergize with other types of interferons for enhanced antiviral activity. The combination has been studied preclinically for its synergistic inhibition of viral replication—particularly acyclovir-resistant herpes simplex virus type 1 (HSV-1)—and may reduce viral loads in both immunocompetent and immunocompromised hosts[1][4]. The mechanism involves cooperative activation of immune pathways leading to reduced viral replication and reactivation.

Other names
IFN-beta + IFN-gammainterferon β + interferon γ
02

Targets

IFNGR1 (Interferon gamma receptor 1)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on interferon beta + interferon gamma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon beta + interferon gamma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call